Department of Thoracic and Breast Surgery, Oita University Faculty of Medicine, Oita, Japan.
Department of Surgery and Science, Kyushu University Graduate School of Medicine, Fukuoka, Japan.
Interact Cardiovasc Thorac Surg. 2022 Jan 18;34(2):219-226. doi: 10.1093/icvts/ivab255.
The ground-glass component of part-solid tumour (PST) was eliminated as a clinical T (cT) descriptor in the eighth edition of the tumour, node and metastasis (TNM) staging system. We aimed to validate the new cT descriptor and investigate the prognostic impact of PST in the new staging system.
Non-small-cell lung cancer (NSCLC) patients (n = 1061) who underwent lung resection and were available for the assessment of thin-section computed tomography images were retrospectively reviewed. Tumours with a solid component (SC) size-to-whole tumour size (STR) ratio of 0, those with 0 < STR < 1 and those with an STR of 1 were defined as pure ground-glass tumours, PSTs and solid tumours (STs), respectively.
Tumours with an SC diameter of >30 mm were less frequently observed among PSTs than among STs (4.83% vs 32.6%, P < 0.001). The postoperative 5-year survival of NSCLC patients with ground-glass tumour, PST and ST was 97.6%, 89.0% and 76.3%, respectively. In the survival analysis of patients with an SC diameter ≤30 mm, significant differences were observed among PST and ST (5-year survival, 90.7% vs 74.6%, P < 0.001). The multivariable analysis showed that age <70 years old, female sex, procedures with a lobectomy or more, SC size, pN0 disease and PST were independent predictors of a better survival among all PST and ST patients.
Among patients with cT1 tumours, those with PST showed a significantly better survival than did those with ST. Small-sized PST tumours may not be suitable for the new cT descriptor.
第八版肿瘤、淋巴结和转移(TNM)分期系统中,部分实性肿瘤(PST)的磨玻璃成分被排除在临床 T(cT)描述之外。我们旨在验证新的 cT 描述符,并研究新分期系统中 PST 的预后影响。
回顾性分析了 1061 例接受肺切除术并可评估薄层计算机断层扫描图像的非小细胞肺癌(NSCLC)患者。肿瘤的实性成分(SC)大小与整个肿瘤大小(STR)的比值为 0、0 < STR < 1 和 STR 为 1 的肿瘤分别定义为纯磨玻璃肿瘤、PST 和实体肿瘤(ST)。
与 ST 相比,PST 中直径 >30mm 的肿瘤较少见(4.83%比 32.6%,P < 0.001)。具有磨玻璃肿瘤、PST 和 ST 的 NSCLC 患者的术后 5 年生存率分别为 97.6%、89.0%和 76.3%。在 SC 直径≤30mm 的患者生存分析中,PST 和 ST 之间存在显著差异(5 年生存率,90.7%比 74.6%,P < 0.001)。多变量分析显示,年龄 <70 岁、女性、肺叶切除术或以上、SC 大小、pN0 疾病和 PST 是所有 PST 和 ST 患者生存更好的独立预测因素。
在 cT1 肿瘤患者中,PST 组的生存明显优于 ST 组。小尺寸的 PST 肿瘤可能不适合新的 cT 描述符。